

## Biophytis to Participate in Upcoming Investor & Partnering Conferences During J.P. Morgan Week 2021

Paris (France), Cambridge (Massachusetts, United States), January 7<sup>th</sup>, 2020, 8:00 a.m. CET - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company developing therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces its management will participate and meet with investors and potential partners at the following upcoming virtual meetings:

- H.C. Wainwright Bioconnect 2021 Conference  
January 11 – 14, 2021
- BIO Partnering @ JPM Week 2021  
January 11 – 15, 2021
- BIOTECH Showcase @JPM Week 2021  
January 11 – 15, 2021

\*\*\*

### About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19.

Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment for sarcopenia in a Phase 2 clinical trial in the US and Europe (SARA-INT). It is also being studied in a clinical two-part Phase 2/3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America and the US.

A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD).

The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). For more information visit [www.biophytis.com](http://www.biophytis.com)

### Disclaimer

This press release contains forward-looking statements. While the Company considers its projections to be based on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from

those anticipated in such forward-looking statements. For a description of the risks and uncertainties likely to affect the results, BIOPHYTIS' financial position, performance or achievements and thus cause a change from the forward-looking statements, please refer to the "Risk Factors" section of the Company's Annual 2019 Report and the Company's Half Year 2020 Report available on BIOPHYTIS website ([www.biophytis.com](http://www.biophytis.com)).

This press release, and the information contained in it, does not constitute an offer to sell or subscribe, nor the solicitation of a purchase or subscription order, of BIOPHYTIS shares in any country. The elements contained in this communication may contain forward-looking information involving risks and uncertainties. The Company's actual achievements may differ materially from those anticipated in this information due to different risk and uncertainty factors. This press release was written in French and English; If there is a difference between the texts, the French version will prevail.

**Biophytis Contact for Investor Relations**

Evelyne Nguyen, CFO

[evelyne.nguyen@biophytis.com](mailto:evelyne.nguyen@biophytis.com)

**Media contact**

***Citigate Dewe Rogerson***

Sylvie Berrebi/ Nathaniel Dahan/ David Dible / Quentin Dussart

[biophytis@citigatedewerogerson.com](mailto:biophytis@citigatedewerogerson.com)

+44 (0) 20 7638 9571 / +33 (0)1 55 30 70 91

Source: Biophytis